Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Leveraging Partnerships to Rescue and Develop Promising Technologies
Posted on November 14th, 2018 by 4P Pharma
Pharma R&D
There are a number of players in the field of innovative therapeutics for cancer and inflammatory disease, but our company, 4P-Pharma, is taking a somewhat different approach than most of our competition. Continue reading “Leveraging Partnerships to Rescue and Develop Promising Technologies” »
There’s nothing more innovative than science – so why don’t we talk about it?
Posted on November 8th, 2018 by Christy J. Wilson
Pharma R&D
Today is – a day where we celebrate the achievements that scientists, technologists, engineers and mathematicians have made through the centuries. It’s also a day which aims to inspire young people to go into STEM subjects by showing them how innovative each of the fields can be. In fact, that’s why November 8th was chosen: N-O-V8—get it? Continue reading “There’s nothing more innovative than science – so why don’t we talk about it?” »
AI in the life sciences – the good, the bad and the ugly
Posted on November 7th, 2018 by Matthew Clark
Pharma R&D
Everyone in the life science industry – from the C-suite in the boardroom to scientists at the bench – are talking about the potential of AI, especially now they’re starting to see pharma companies using the technology. And we are beginning to see researchers mixing diverse kinds of data together – images, text and numeric data to name a few – to learn from. Continue reading “AI in the life sciences – the good, the bad and the ugly” »
Machine Learning Could Make Drug Discovery Faster, Cheaper, Better
Posted on November 6th, 2018 by Jabe Wilson
Pharma R&D
The stats on the increasingly high cost (and low success rates) in drug discovery are always jarring. As Phee Waterfield of Binary District Journal reports:
- Bringing a new drug to market is estimated to cost major pharma firms more than $4 billion
- The process can take 10-15 years
- Fewer than 10% actually make it to market
Continue reading “Machine Learning Could Make Drug Discovery Faster, Cheaper, Better” »
How Greater Collaboration and Access to Data can Help Tackle Rare Diseases
Posted on November 1st, 2018 by Jabe Wilson
Pharma R&D
It is estimated that 30 million people in the United States alone are living with one of 7,000 rare diseases, this equates to 10% of the population. There is, however, little financial incentive for the pharmaceutical sector to develop new treatments for these diseases because of the small patient population each disease affects. Continue reading “How Greater Collaboration and Access to Data can Help Tackle Rare Diseases” »
Experts Gather for a Pair of Pharma & Biotech Conferences
Posted on October 22nd, 2018 by Christy J. Wilson
Pharma R&D
From October 29-30, London will be the site of two important events for the pharma and biotech industries, the 2nd Medicinal Chemistry Summit: Europe and the 2nd Global Pharma R&D Informatics & AI Congress. Presented by Global Engage, the conferences will be co-located at the Radisson Blu Edwardian Heathrow, opening up the opportunity for industry professionals to sample what each has to offer. Continue reading “Experts Gather for a Pair of Pharma & Biotech Conferences” »
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.
